Langrish CL - Search Results

1

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.

Langrish CL, Bradshaw JM, Francesco MR, Owens TD, Xing Y, Shu J, LaStant J, Bisconte A, Outerbridge C, White SD, Hill RJ, Brameld KA, Goldstein DM, Nunn PA. Langrish CL, et al. J Immunol. 2021 Apr 1;206(7):1454-1468. doi: 10.4049/jimmunol.2001130. Epub 2021 Mar 5. J Immunol. 2021. PMID: 33674445 Free PMC article.

2

PRN473, an inhibitor of Bruton's tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling.

Herter JM, Margraf A, Volmering S, Correia BE, Bradshaw JM, Bisconte A, Hill RJ, Langrish CL, Lowell CA, Zarbock A. Herter JM, et al. Among authors: langrish cl. Br J Pharmacol. 2018 Feb;175(3):429-439. doi: 10.1111/bph.14090. Epub 2017 Dec 22. Br J Pharmacol. 2018. PMID: 29130484 Free PMC article.

3

Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models.

Xing Y, Chu KA, Wadhwa J, Chen W, Zhu J, Bradshaw JM, Shu J, Foulke MC, Loewenstein N, Nunn P, By K, Phiasivongsa P, Goldstein DM, Langrish CL. Xing Y, et al. Among authors: langrish cl. Immunohorizons. 2021 Jul 29;5(7):581-589. doi: 10.4049/immunohorizons.2100063. Immunohorizons. 2021. PMID: 34326199 Free article.

4

Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).

Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE, Hartmann S, Francesco MR, Langrish CL, Nunn PA, Gourlay SG. Owens TD, et al. Among authors: langrish cl. Clin Transl Sci. 2022 Feb;15(2):442-450. doi: 10.1111/cts.13162. Epub 2021 Nov 12. Clin Transl Sci. 2022. PMID: 34724345 Free PMC article. Clinical Trial.

5

Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

Owens TD, Brameld KA, Verner EJ, Ton T, Li X, Zhu J, Masjedizadeh MR, Bradshaw JM, Hill RJ, Tam D, Bisconte A, Kim EO, Francesco M, Xing Y, Shu J, Karr D, LaStant J, Finkle D, Loewenstein N, Haberstock-Debic H, Taylor MJ, Nunn P, Langrish CL, Goldstein DM. Owens TD, et al. Among authors: langrish cl. J Med Chem. 2022 Apr 14;65(7):5300-5316. doi: 10.1021/acs.jmedchem.1c01170. Epub 2022 Mar 18. J Med Chem. 2022. PMID: 35302767

6

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M. Basler M, et al. Among authors: langrish cl. EMBO Rep. 2018 Dec;19(12):e46512. doi: 10.15252/embr.201846512. Epub 2018 Oct 2. EMBO Rep. 2018. PMID: 30279279 Free PMC article.

7

Cutting edge: Modulation of intestinal autoimmunity and IL-2 signaling by sphingosine kinase 2 independent of sphingosine 1-phosphate.

Samy ET, Meyer CA, Caplazi P, Langrish CL, Lora JM, Bluethmann H, Peng SL. Samy ET, et al. Among authors: langrish cl. J Immunol. 2007 Nov 1;179(9):5644-8. doi: 10.4049/jimmunol.179.9.5644. J Immunol. 2007. PMID: 17947634

8

Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.

Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, Blumenschein W, Churakovsa T, Low J, Presta L, Hunter CA, Kastelein RA, Cua DJ. Chen Y, et al. Among authors: langrish cl. J Clin Invest. 2006 May;116(5):1317-26. doi: 10.1172/JCI25308. J Clin Invest. 2006. PMID: 16670771 Free PMC article.

9

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.

Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Murphy CA, et al. Among authors: langrish cl. J Exp Med. 2003 Dec 15;198(12):1951-7. doi: 10.1084/jem.20030896. Epub 2003 Dec 8. J Exp Med. 2003. PMID: 14662908 Free PMC article.

10

IL-12 and IL-23: master regulators of innate and adaptive immunity.

Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. Langrish CL, et al. Immunol Rev. 2004 Dec;202:96-105. doi: 10.1111/j.0105-2896.2004.00214.x. Immunol Rev. 2004. PMID: 15546388 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters